Ankyra Therapeutics News and Activities

View the org chart displaying its 16 main executives

Most searched biographies at Ankyra Therapeutics

• Howard Kaufman, Chief Executive Officer and Director
• Julia Butchko, Director
• Tillman Gerngross, Chairman of the Board

Create your alert
to follow the executive moves at Ankyra Therapeutics.

Ankyra Therapeutics has 2,405 competitors including Lonza (Switzerland), Eurofins (Luxembourg) and Vertex Pharmaceuticals (United States (USA)).

Popular M&A news in Biotechnology

• Ona Therapeutics has just announced a $87 Million fundraising (posted on June 5 2026).
• Laboratoire Servier has announced the acquisition of Edgewise Therapeutics  (posted on June 4 2026).
• Oak Hill Bio has just announced a $33 Million fundraising (posted on June 4 2026).

Popular contacts in Biotechnology

• Jakob Uszkoreit - Co-Founder and Chief Executive Officer at Inceptive
• Jan Van de Winkel - President and Chief Executive Officer at Genmab
• Carl Gordon - Director at Odyssey Therapeutics

Learn more about the Biotechnology industry

Press releases by Ankyra Therapeutics

• Ankyra Therapeutics Announces Presentations on Novel IL-12 Anchored Immunotherapy at 2026 ASCO - Ankyra
• Ankyra Therapeutics Announces Preclinical Presentation of Anchored Immunotherapy Using Monoclonal Antibodies at PEGS Boston 2026 - Ankyra
• Ankyra Therapeutics Announces Clinical Presentations on Novel IL-12 Anchored Immunotherapy at AACR 2026 - Ankyra
• Ankyra Therapeutics Presents First Preclinical Data on ANK-203, a Novel CD137-Anchored Immunotherapy Candidate, in Oral Session at AACR IO - Ankyra
• Ankyra appoints Sailaja Battula, PhD as chief scientific officer (CSO) - Ankyra
• Ankyra Therapeutics Announces First Patient Dosed in Phase 1b Trial Evaluating First-in-Class Anchored Immunotherapy in Combination with Immune Checkpoint Blockade in Patients with Lung Cancer - Ankyra
• Ankyra announces publication of Phase 1 clinical data, and will present at the Society for Immunotherapy of Cancer (SITC) annual meeting - Ankyra
• Ankyra Therapeutics Announces Phase 1 Clinical Data at the 2025 AACR Annual Meeting and the first patient has been dosed with tolododekin alfa and cemiplimab - Ankyra
• Ankyra Therapeutics Announces Expansion of Existing Collaboration to advance IL-12 Anchored Drug Conjugate in Patients with Lung Cancer - Ankyra
• Ankyra Announces Appointment of Dr. Julia Butchko and Ms. Tara Withington to the Board of Directors - Ankyra
• View more press releases Close

Social media about Ankyra Therapeutics

• Ankyra Therapeutics on Wikipedia, Google News & Yahoo Finance
• Ankyra Therapeutics on LinkedIn, X (Twitter) & YouTube